{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=All&page=73",
    "query": {
      "condition": "All",
      "page": 73
    },
    "page_size": 10
  },
  "pagination": {
    "page": 73,
    "page_size": 10,
    "total_count": 2206,
    "total_pages": 221,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=All&page=74&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=All&page=72&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T10:54:03.484Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06773936",
      "title": "Adding Asciminib to Usual Treatment for Adults With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
        "CD19+ Acute Leukemia"
      ],
      "interventions": [
        {
          "name": "Induction Phase",
          "type": "DRUG"
        },
        {
          "name": "Re-Induction Phase",
          "type": "DRUG"
        },
        {
          "name": "Post-Remission",
          "type": "DRUG"
        },
        {
          "name": "Maintenance",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 55,
      "start_date": "2026-04-13",
      "completion_date": "2033-07",
      "has_results": false,
      "last_update_posted_date": "2026-10-05",
      "last_synced_at": "2026-11-04T10:54:03.484Z",
      "location_count": 16,
      "location_summary": "Tucson, Arizona • Orange, California • Detroit, Michigan + 11 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Bellevue",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06773936"
    },
    {
      "nct_id": "NCT00002750",
      "title": "Melphalan in Patients With Neoplastic Meningitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Extragonadal Germ Cell Tumor",
        "Leukemia",
        "Lymphoma",
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "melphalan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "3 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "1992-12",
      "completion_date": "2001-05",
      "has_results": false,
      "last_update_posted_date": "2013-02-20",
      "last_synced_at": "2026-11-04T10:54:03.484Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002750"
    },
    {
      "nct_id": "NCT03136146",
      "title": "Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Acute Lymphoblastic Leukemia",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Burkitt Leukemia",
        "Recurrent Burkitt Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Refractory Acute Lymphoblastic Leukemia",
        "Refractory Burkitt Leukemia",
        "Refractory Burkitt Lymphoma",
        "Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements",
        "Refractory Lymphoblastic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Bortezomib",
          "type": "DRUG"
        },
        {
          "name": "Clofarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Ofatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pegfilgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Vincristine Sulfate Liposome",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2017-08-09",
      "completion_date": "2027-08-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-10",
      "last_synced_at": "2026-11-04T10:54:03.484Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03136146"
    },
    {
      "nct_id": "NCT00096161",
      "title": "Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Acute Myeloid Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Graft Versus Host Disease",
        "Hodgkin Lymphoma",
        "Myelodysplastic/Myeloproliferative Neoplasm",
        "Non-Hodgkin Lymphoma",
        "Plasma Cell Myeloma",
        "Waldenstrom Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate Mofetil",
          "type": "DRUG"
        },
        {
          "name": "Pentostatin",
          "type": "DRUG"
        },
        {
          "name": "Therapeutic Allogeneic Lymphocytes",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 36,
      "start_date": "2003-05",
      "completion_date": "2015-08",
      "has_results": true,
      "last_update_posted_date": "2020-01-31",
      "last_synced_at": "2026-11-04T10:54:03.484Z",
      "location_count": 4,
      "location_summary": "Salt Lake City, Utah • Seattle, Washington",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00096161"
    },
    {
      "nct_id": "NCT01363297",
      "title": "Study Evaluating Inotuzumab Ozogamicin In Acute Lymphocytic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Inotuzumab Ozogamicin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2011-08",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2017-04-13",
      "last_synced_at": "2026-11-04T10:54:03.484Z",
      "location_count": 15,
      "location_summary": "Duarte, California • Palo Alto, California • Stanford, California + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01363297"
    },
    {
      "nct_id": "NCT03448991",
      "title": "Effect of NPO Time and Type of Food Intake on Preoperative Residual Gastric Content and pH",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fasting",
        "Pediatric ALL"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "Up to 17 Years"
      },
      "enrollment_count": 150,
      "start_date": "2018-08-24",
      "completion_date": "2019-12-11",
      "has_results": false,
      "last_update_posted_date": "2021-01-19",
      "last_synced_at": "2026-11-04T10:54:03.484Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03448991"
    },
    {
      "nct_id": "NCT03562910",
      "title": "Mobile-based Social Services Screening and Referral Tool in an Pediatric Emergency Department",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Poverty",
        "Social Determinants of Health",
        "Mobile Applications",
        "Pediatric ALL",
        "Emergencies"
      ],
      "interventions": [
        {
          "name": "HelpSteps application",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 266,
      "start_date": "2019-05-13",
      "completion_date": "2020-12-11",
      "has_results": false,
      "last_update_posted_date": "2021-03-02",
      "last_synced_at": "2026-11-04T10:54:03.484Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03562910"
    },
    {
      "nct_id": "NCT01434342",
      "title": "Feasibility of Delivering a Quitline Based Smoking Cessation Intervention in Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Lung Cancer",
        "Tobacco Use Disorder",
        "Breast Cancer",
        "Colorectal Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Nicotine Replacement Patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Wake Forest University Health Sciences",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 146,
      "start_date": "2011-10-01",
      "completion_date": "2015-01-01",
      "has_results": true,
      "last_update_posted_date": "2021-09-28",
      "last_synced_at": "2026-11-04T10:54:03.484Z",
      "location_count": 1,
      "location_summary": "Winston-Salem, North Carolina",
      "locations": [
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01434342"
    },
    {
      "nct_id": "NCT00725062",
      "title": "Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Graft Versus Host Disease",
        "Leukemia",
        "Lymphoma",
        "Multiple Myeloma and Plasma Cell Neoplasm",
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "CD4+CD25+ regulatory T cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 3,
      "start_date": "2008-06",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2017-11-29",
      "last_synced_at": "2026-11-04T10:54:03.484Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00725062"
    },
    {
      "nct_id": "NCT03594162",
      "title": "Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "Immune System Diseases",
        "Immunoproliferative Disorders"
      ],
      "interventions": [
        {
          "name": "iC9-CAR19 cells",
          "type": "DRUG"
        },
        {
          "name": "AP1903",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "3 Years to 70 Years"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2021-12-03",
      "last_synced_at": "2026-11-04T10:54:03.484Z",
      "location_count": 1,
      "location_summary": "Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03594162"
    }
  ]
}